Real-world precision medicine data in metastatic prostate cancer - a retrospective cohort study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
200 patients with metastatic hormone sensitive (mHSPC) and castration resistant (mCRPC) prostate cancer who had a FoundationOne report and were treated from June 2007 to October 2024 were included in the study.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
mutations are associated with shorter OS only in mHSPC. and mutations were associated with shorter PFS only in mCRPC.
[BACKGROUND] Prostate cancer (PC) is the most common cancer in men in the United States with a 5-year relative survival rate for people with distant metastases of 36%.
- 표본수 (n) 99
- p-value p<0.01
- p-value p=0.03
- 연구 설계 cohort study
APA
Paracha A, Tran D, et al. (2026). Real-world precision medicine data in metastatic prostate cancer - a retrospective cohort study.. Frontiers in oncology, 16, 1772860. https://doi.org/10.3389/fonc.2026.1772860
MLA
Paracha A, et al.. "Real-world precision medicine data in metastatic prostate cancer - a retrospective cohort study.." Frontiers in oncology, vol. 16, 2026, pp. 1772860.
PMID
41878526
Abstract
[BACKGROUND] Prostate cancer (PC) is the most common cancer in men in the United States with a 5-year relative survival rate for people with distant metastases of 36%. We conducted a single institution, retrospective cohort study of patients with metastatic PC to investigate whether certain gene mutations can be used as predictive biomarkers.
[METHODS] 200 patients with metastatic hormone sensitive (mHSPC) and castration resistant (mCRPC) prostate cancer who had a FoundationOne report and were treated from June 2007 to October 2024 were included in the study. Disease progression was evaluated according to RECIST criteria, PCWG3 criteria, and PSA values. Assessed gene mutations included , and genes. Overall survival (OS) and progression-free survival (PFS) were calculated for mHSPC and mCRPC.
[RESULTS] Among 200 patients, there were 182 patients with mHSPC and 174 patients with mCRPC. Average age at diagnosis of metastatic disease was 71.5, ECOG was 0.76, and median PSA was 75.6 ng/mL. 152 patients had high-volume disease. 102 patients passed away. Patients with a mutation (n=99) had lower OS in mHSPC (50.7 months vs 86.2 months, p<0.01). Patients with a mutation (n=50) had a lower OS in mHSPC (50.6 months vs 65.8 months, p=0.03) and mCRPC (29.5 months vs 46.0 months, p=0.04). Patients with mutations (n=43) had lower OS in mHSPC (41.4 months vs 64.6 months, p<0.01) and mCRPC (18.4 months vs 42.8 months, p=0.04). and mutations were associated with shorter PFS in mCRPC (13.8 months vs 23.2 months, p=0.03; 12.2 months vs 22.6 months, p<0.01, respectively). Mutations in (n=13 mHSPC, n=9 mCRPC) and (n=12 mHSPC, n=10 mCRPC) were not associated with statistically significant differences in OS and PFS.
[CONCLUSIONS] , and mutations were associated with shorter OS in both mHSPC and mCRPC. mutations are associated with shorter OS only in mHSPC. and mutations were associated with shorter PFS only in mCRPC.
[METHODS] 200 patients with metastatic hormone sensitive (mHSPC) and castration resistant (mCRPC) prostate cancer who had a FoundationOne report and were treated from June 2007 to October 2024 were included in the study. Disease progression was evaluated according to RECIST criteria, PCWG3 criteria, and PSA values. Assessed gene mutations included , and genes. Overall survival (OS) and progression-free survival (PFS) were calculated for mHSPC and mCRPC.
[RESULTS] Among 200 patients, there were 182 patients with mHSPC and 174 patients with mCRPC. Average age at diagnosis of metastatic disease was 71.5, ECOG was 0.76, and median PSA was 75.6 ng/mL. 152 patients had high-volume disease. 102 patients passed away. Patients with a mutation (n=99) had lower OS in mHSPC (50.7 months vs 86.2 months, p<0.01). Patients with a mutation (n=50) had a lower OS in mHSPC (50.6 months vs 65.8 months, p=0.03) and mCRPC (29.5 months vs 46.0 months, p=0.04). Patients with mutations (n=43) had lower OS in mHSPC (41.4 months vs 64.6 months, p<0.01) and mCRPC (18.4 months vs 42.8 months, p=0.04). and mutations were associated with shorter PFS in mCRPC (13.8 months vs 23.2 months, p=0.03; 12.2 months vs 22.6 months, p<0.01, respectively). Mutations in (n=13 mHSPC, n=9 mCRPC) and (n=12 mHSPC, n=10 mCRPC) were not associated with statistically significant differences in OS and PFS.
[CONCLUSIONS] , and mutations were associated with shorter OS in both mHSPC and mCRPC. mutations are associated with shorter OS only in mHSPC. and mutations were associated with shorter PFS only in mCRPC.